Results 81 to 90 of about 24,933,173 (248)

Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2 [PDF]

Proceedings of the National Academy of Sciences, 1999
Janus kinases (JAKs) are cytoplasmic tyrosine kinases critical for signaling by growth hormone (GH) and many other ligands that bind to members of the cytokine receptor superfamily. SH2-Bβ was previously identified as a JAK2-interacting protein that is tyrosyl phosphorylated in response to GH and other cytokines that activate JAK2.
L, Rui, C, Carter-Su
openaire   +2 more sources

Advancing Biotherapeutic Treatment of Ulcerative Colitis Using Lipid Mesophases: Formulation Design and Preclinical Validation

Advanced Science, EarlyView.
Lipid mesophases provide a versatile platform for colon‐targeted delivery of biotherapeutics, protecting them from degradation while enhancing mucoadhesion and enabling localized, controlled release to the inflamed mucosa after oral or rectal administration. In a DSS‐induced colitis model, this strategy reduced disease activity, inflammatory biomarkers,
Rafaela Gazzi, Tiziana Cremona, Reto Czekalla, Emily Campbell, Marlene Schwarzfischer, Doris Pöhlmann, Vanessa Dobernig, Gerhard Rogler, Michael Scharl, Alessandra Bergadano, Raffaele Mezzenga, Martin Kuentz, Paola Luciani, Simone Aleandri   +13 more
wiley   +1 more source

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis

Nature Communications
Tofacitinib, a pan–Janus kinase inhibitor, and the Janus kinase 1–preferential inhibitors Upadacitinib and Filgotinib are approved for the treatment of ulcerative colitis, yet their molecular mechanisms of action remain incompletely understood.
Beibei Liu, Marianne R. Spalinger, Annalisa Invernizzi, Eike Gerdes, Babett Steglich, Marlene Schwarzfischer, Andres Machicote, Penelope Pelczar, Doris Pöhlmann, Mikolaj Nawrocki, Marius Böttcher, Ayob Aleko, Lis Noelia Velasquez, Sandra Wende, Franziska Stallbaum, Justus Neuendorff, Saskia Grosshauser, Franziska Muscate, Gemma Douilhet, Laura Garcia Perez, Morsal Sabihi, Katharina Möller, Florian Viehweger, Jan P. Sutter, Christoph Kilian, Yogesh Kumar, Thorben Fründt, Guido Sauter, Thomas Rösch, Nicola Gagliani, Amedeo Caflisch, Michael Scharl, Samuel Huber   +32 more
doaj   +1 more source

Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation

, 2013
Pyoderma gangrenosum (PG) commonly occurs in association with various haematological and inflammatory disorders. We report a new association, a Janus kinase (JAK)2 mutation, in a 63-year-old patient with PG.
Levell, N. J., Macbeth, A. E., Palanivel, J. A.   +2 more
core   +1 more source

Deep evolutionary conservation of an intramolecular protein kinase activation mechanism [PDF]

, 2012
DYRK-family kinases employ an intramolecular mechanism to autophosphorylate a critical tyrosine residue in the activation loop. Once phosphorylated, DYRKs lose tyrosine kinase activity and function as serine/threonine kinases.
Cleghon Vaughn, Aman Singh (191216), Cleghon, V., Nathan Luebbering (191210), Sibbet Gary, Jingfen Han, Luebbering Nathan, Nathan Luebbering, Michael A J Ferguson, Singh, A., Aman Singh, Ferguson, M.A.J., Ferguson Michael A. J., Hong, W., Diego Miranda-Saavedra (36622), Michael A. J. Ferguson (166662), Jingfen Han, Han, J., Gary Sibbet (191221), Vaughn Cleghon (191224), Miranda-Saavedra Diego, Sibbet, G., Ferguson, M.A.J.; id_orcid, Han Jingfen, Miranda-Saavedra, D., Gary Sibbet, Luebbering, N., Diego Miranda-Saavedra, Michael A. J. Ferguson, Vaughn Cleghon, Singh Aman, Jingfen Han (191204)   +31 more
core   +1 more source

RBMS1 Contributes to Early Arteriovenous Fistula Neointimal Remodeling Through Modulation of VSMC Phenotypic Responses

Advanced Science, EarlyView.
Postoperative arteriovenous fistulas exhibit increased RBMS1 in vascular smooth muscle cells (VSMCs). In experimental AVFs, RBMS1 overexpression aggravates, whereas deletion attenuates, neointimal hyperplasia. RBMS1 binds MPZL1 mRNA and promotes exon 5 skipping to generate MPZL1‐Δ5, which interacts with G3BP1 to activate AKT, driving VSMC proliferation,
Zongda Li, Chengwei Zhang, Xinying Yu, Shuang Yao, Yiting Lai, Xiaozhu Sun, Yao Zhao, Xiaoyu Lan, Tingting Hu, Wenjin Li, Zhenzhen Ma, Huimin Ma, Zihan Wang, Haihai Liang, Jundong Jiao   +14 more
wiley   +1 more source

Structural and functional characterization of the intracellular kinase domain of vascular endothelial growth factor receptor-2 [PDF]

, 2013
Vascular Endothelial Growth Factors (VEGFs) are key players in blood and lymphatic vessel development and homeostasis. The family consists of five members, VEGF-A, -B, -C, -D and placenta growth factor (PLGF).
Manni, Sandro
core   +1 more source

Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama   +4 more
wiley   +1 more source

The potency of native postbiotics and paraprobiotics in modulating inflammation by affecting the gut–kidney axis

Animal Models and Experimental Medicine, EarlyView.
Native postbiotics and paraprobiotics derived from Lactobacillus and Bifidobacterium strains were administered to dextran sulfate sodium–treated C57BL/6 mice to evaluate their impact on kidney inflammation via the gut–kidney axis. Histological analysis and quantitative polymerase chain reaction of autophagy‐related genes (atg5, atg7, atg12, atg13 ...
Fatemeh Haririzadeh Jouriani, Mahnaz Torfeh, Fatemeh Ashrafian, Niloofar Rezaie, Mohsen Mohammadi, Shadi Aghamohammad, Mahdi Rohani   +6 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source